Pegylated liposomal doxorubicin HCL (PLD; Caelyx/Doxil®): Experience with long-term maintenance in responding patients with recurrent epithelial ovarian cancer

Annals of Oncology

Volumn 18, Issue 4, 2007, Pages 716-721

  Andreopoulou, E ^a   Gaiotti, D ^a   Kim, E ^b   Downey, A ^a   Mirchandani, D ^a   Hamilton, A ^a,c   Jacobs, Allan ^a   Curtin, John ^a   Muggia, F ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^c ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Liposomal doxorubicin; Maintenance therapy; Ovarian cancer

Indexed keywords

CARBOPLATIN; DOXORUBICIN; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER RELAPSE; CARDIOGENIC SHOCK; CARDIOTOXICITY; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HOSPITALIZATION; HUMAN; HYPERPIGMENTATION; HYPERTENSION; HYPOTHESIS; INFECTION; LONG TERM CARE; MAINTENANCE THERAPY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; PANCYTOPENIA; PRIORITY JOURNAL; SKIN TOXICITY; THROMBOCYTOPENIA; UTERINE TUBE TUMOR;

AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; POLYETHYLENE GLYCOLS;

EID: 34047158249     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl484     Document Type: Article

References (41)

1. Markman M, Liu PY, Wilczynski S et al. Southwest Oncology Group; Gynecologic Oncology Group. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol 2003; 21 (13): 2460-2465.
2. Bolis G, Scarfone G, Sciatta C et al. A phase I/II study of topotecan in combination with carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001; 83: 477-480.
3. Pfisterer J, Vergote I, Du Bois A, Eisenhauer E, AGO-OVAR; NCIC CTG; EORTC GCG. Combination therapy with gemcitabine and carboplatin in recurrent ovarian cancer. Int J Gynecol Cancer 2005; 15 (Suppl 1): 36-41.
4. Guastalla JP, Pujade-Lauraine E, Weber B et al. Efficacy and safety of the paclitaxel and carboplatin combination in patients with previously treated advanced ovarian carcinoma: A multicenter GINECO (Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens) phase II study. Ann Oncol 1998; 9: 37-43.
5. Gronlund B, Hogdall C, Hansen HH et al. Results of reinduction therapy with paclitaxel and carboplatin in recurrent epithelial ovarian cancer. Gynecol Oncol 2001; 83: 128-134.
6. Rose PG, Fusco N, Fluellen L et al. Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma. J Clin Oncol 1998; 16: 1494-1497.
7. Dizon DS, Hensley ML, Poynor EA et al. Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: Application toward a dynamic disease state model of ovarian cancer. J Clin Oncol 2002; 20 (5): 1238-1247.
8. Markman M, Markman J, Webster K et al. Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol 2004; 22 (15): 3120-3125.
9. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: Antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15 (3): 987-993.
10. Gordon AN, Granai CO, Rose PG et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18 (17): 3093-3100.
11. Safra T. Cardiac safety of liposomal anthracyclines. Oncologist 2003; 8 (Suppl 2): 17-24.
12. Rose PG, Maxson JH, Fusco N et al. Liposomal doxorubicin in ovarian, peritoneal, and tubal carcinoma: A retrospective comparative study of single-agent dosages. Gynecol Oncol 2001; 82 (2): 323-328.
13. Campos SM, Penson RT, Mays AR et al. The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol 2001; 81 (2): 206-212.
14. Safra T, Groshen S, Jeffers S et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: Analysis of toxicities and predictors of outcome. Cancer 2001; 91 (1): 90-100.
15. Northfelt DW, Martin FJ, Working P et al. Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36 (1): 55-63.
16. Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998; 9 (7): 711-716.
17. Opravil M, Tomlinson D, Bogner JR. Caelyx (doxil; liposomal doxorubicin) is tolerated well long-term at high cumulative dose in AIDS-related Kaposi's sarcoma (AIDS-KS) patients - a meta-analysis of 1716 patients. Proc Am Soc Clin Oncol 1998; 17: (Abstr 257).
18. Mustafa MH. Decreased risk of cardiotoxicity with long-term use of doxil/ caelyx at high lifetime cumulative doses in patients with AIDS-related Kaposi/Es sarcoma (KS). Proc Am Soc Clin Oncol 2001; 20: (Abstr 2915).
19. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol 2000; 78 (3 Pt 1): 369-372.
20. 2. Ann Oncol 2000; 11 (8): 1029-1033.
21. Klein P, Lyass O, Sorich J et al. Doxil plus cisplatin: Combined results of two phase I studies. Proc Am Soc Clin Oncol 1998; 17: (Abstr 942).
22. Mirchandani D, Hochster H, Hamilton A et al. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer. Clin Cancer Res 2005; 11 (16): 5912-5919.
23. Hamilton AL, Pavlick A, Volm M et al. Pegylated liposomal doxorubicin (PLD) and carboplatin (C): A phase I study of combination therapy with maintenance PLD. Proc Am Soc Clin Oncol 2003; 22: 494 (Abstr 1986).
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92 (3): 205-216.
25. Liu P, Alberts DS, Monk BJ et al. Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received "maintenance therapy". Proc Am Soc Clin Oncol 2005; 24: 458 (Abstr 5013).
26. Liu P, Moon J, Alberts DS et al. A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy. Proc Am Soc Clin Oncol 2006; 25: (Abstr 5080).
27. Markman M, Liu PY, Rothenberg ML et al. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer. J Clin Oncol 2006; 24 (9): 1454-1458.
28. Spriggs D. Optimal sequencing in the treatment of recurrent ovarian cancer. Gynecol Oncol 2003; 90 (3 Suppl 1): S39-S44.
29. Spriggs D. Duration of therapy for ovarian cancer: How long is enough? Cancer Invest 2004; 1 (Suppl): 44.
30. Ozols RF. Maintenance therapy in advanced ovarian cancer: progression-free survival and clinical benefit. J Clin Oncol 2003; 21 (13): 2451-2453.
31. Gabizon AA, Lyass O. Cardiac safety of pegylated liposomal doxorubicin (PLD) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003; 22: 763a.
32. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (caelyx/doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004; 15 (3): 440-449.
33. Vaage J, Donovan D, Mayhew E et al. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer 1993; 72 (12): 3671-3675.
34. Gabizon A, Shmeeda H, Barenholz Y [Review]. Pharmacokinetics of pegylated liposomal doxorubicin: Review of animal and human studies. Clin Pharmacokinet 2003; 42 (5): 419-436.
35. Gabizon A, Catane R, Uziely B et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethyleneglycol coated liposomes. Cancer Res 1994; 54 (4): 987-992.
36. Gabizon AA. Stealth liposomes and tumor targeting: One step further in the quest for the magic bullet. Clin Cancer Res 2001; 7 (2): 223-225.
37. Huang SK, Lee KD, Hong K et al. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearingmice. Cancer Res 1992; 52 (19): 5135-5143.
38. Yuan F, Leunig M, Huang SK et al. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54 (13): 3352-3356.
39. Allen TM. Liposomes. Opportunities in drug delivery. Drugs 1997; 54 (Suppl 4): 8-14.
40. Uyar D, Kulp B, Peterson G et al. Cardiac safety profile of prolonged (>or = 6 cycles) pegylated liposomal doxorubicin administration in patients with gynecologic malignancies. Gynecol Oncol 2004; 94 (1): 147-151.
41. Gordon AN, Tonda M, Sun S, Rackoff W. Doxil study 30-49 investigators. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95 (1): 1-8.